Are Peptides Legal in Massachusetts? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Massachusetts as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Massachusetts attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Massachusetts statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Massachusetts has scheduled or banned on its own. Massachusetts also lists human growth hormone in its own controlled-substance law, on top of the federal rule. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Massachusetts at a glance

State controlled-substances law: Massachusetts Controlled Substances Act, M.G.L. c. 94C (classes A to E at § 31); Department of Public Health schedules at 105 CMR 700.002, which adopt the federal Schedules I to V and define Schedule VI (Class E) as every prescription drug not in another schedule (law.cornell.edu)
Human growth hormone under state law: Listed as a controlled substance in state law (105 CMR 700.002 (Schedule VI, Class E catch-all), implementing M.G.L. c. 94C § 31) (law.cornell.edu)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: No statement located
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Yes. Board of Registration in Medicine Policy 2020-01 (amended 3 February 2022) says the practice of medicine does not require a face-to-face encounter before care via telemedicine and that the standard of care is the same as in person; M.G.L. c. 112 § 5O defines telehealth to include online adaptive interviews for prescribing. No questionnaire-specific ban was found in the policy. (archives.lib.state.ma.us)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence low

The federal rules that apply in Massachusetts, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Massachusetts:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Massachusetts. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Massachusetts law adds

Massachusetts's controlled-substances law (Massachusetts Controlled Substances Act, M.G.L. c. 94C (classes A to E at § 31); Department of Public Health schedules at 105 CMR 700.002, which adopt the federal Schedules I to V and define Schedule VI (Class E) as every prescription drug not in another schedule) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (law.cornell.edu)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Massachusetts's schedules or in a Massachusetts-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Massachusetts does not name HGH, but unlike most states it treats every prescription drug not in Schedules I to V as a Schedule VI (Class E) controlled substance, so somatropin, semaglutide, tirzepatide and other prescription peptides are Class E in Massachusetts. This is a catch-all for all prescription drugs, not a peptide-specific restriction. (105 CMR 700.002 (Schedule VI, Class E catch-all), implementing M.G.L. c. 94C § 31) (law.cornell.edu)

Compounded semaglutide and tirzepatide

No Massachusetts Board of Pharmacy statement specific to compounded GLP-1 drugs was located. Licensed Massachusetts pharmacies follow the federal 503A and 503B rules, under which the shortage exception for semaglutide and tirzepatide has ended.

Clinics, medspas and prescribers

No Massachusetts medical board guidance specific to peptide therapy was located. A Massachusetts prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Massachusetts

Because 105 CMR 700.002 makes all prescription drugs Class E controlled substances, possessing a prescription-only peptide such as semaglutide or HGH without a prescription can be charged as Class E possession under M.G.L. c. 94C § 34, whereas a substance that is not an approved prescription drug and is not federally scheduled, such as BPC-157 or TB-500 sold as a research chemical, falls in no Massachusetts class and its possession is not a state drug offence; the federal rules bind sellers. (law.cornell.edu)

Ordering from a vendor in another state. Almost every research-peptide order into Massachusetts is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. Board of Registration in Medicine Policy 2020-01 (amended 3 February 2022) says the practice of medicine does not require a face-to-face encounter before care via telemedicine and that the standard of care is the same as in person; M.G.L. c. 112 § 5O defines telehealth to include online adaptive interviews for prescribing. No questionnaire-specific ban was found in the policy. (archives.lib.state.ma.us) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Massachusetts law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Massachusetts

2025-02-19. Massachusetts' attorney general joined the 38-state letter urging the FDA to act against counterfeit and illegally sold GLP-1 drugs, including research-only sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The Massachusetts legislature's site and its mirrors refused connections during this check, so M.G.L. c. 94C §§ 31 and 34 were not opened and the Class E analysis rests on the regulation alone. Board of Registration in Pharmacy Policy 2020-02 on compounding copies of commercially available drugs, and April 2025 board minutes on a complaint over compounded oral semaglutide, surfaced in search results but could not be opened.

Frequently asked questions

Is BPC-157 legal in Massachusetts?

Massachusetts has not scheduled BPC-157, so possessing it is not a Massachusetts offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Massachusetts?

Yes. Board of Registration in Medicine Policy 2020-01 (amended 3 February 2022) says the practice of medicine does not require a face-to-face encounter before care via telemedicine and that the standard of care is the same as in person; M.G.L. c. 112 § 5O defines telehealth to include online adaptive interviews for prescribing. No questionnaire-specific ban was found in the policy. Compounded versions are no longer covered by the FDA's shortage exception, and the FDA has proposed keeping semaglutide and tirzepatide off the 503B bulks list, so expect availability of compounded product to keep shrinking.

Is HGH legal in Massachusetts?

Only with a valid prescription. Massachusetts lists human growth hormone as a controlled substance and federal law, 21 U.S.C. section 333(e), separately makes distribution or possession for a non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Massachusetts fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.